Research on the Optimization of Pharmacovigilance Laws and Regulations in China

Abstract

Objective To analyze the problems of China’s pharmacovigilance legislation, and to provide some suggestions for improving it. Methods Relevant literature at home and abroad were studied to compare the laws and regulations of the United States, the European Union, Japan and China. Then, the problems of China’s pharmacovigilance legislation were analyzed. Results and Conclusion The Chinese pharmacovigilance legislation has such problems as nontransparent formulation process, poor dynamic adaptability, insufficient use of the attention mechanism, fragmentation of laws and regulations, and poor connection of laws and regulations, which should be optimized. It is recommended to carry out theoretical and methodological research on pharmacovigilance legislation to provide practical guidance for optimizing pharmacovigilance legislation with Chinese characteristics.

Keywords

pharmacovigilance laws and regulations / system optimization / policy recommendations

References

[1] FDA. FD&C Act Chapter V:Drugs and Devices[EB/OL]. (2020-01-17)[2023-02-21]. https:/www.fda.gov/regulatory-information/federal-food-drug-and-cosmetic-act-fdc-act/fdc-act-chapter-v-drugs-and-devices#Part_A.

[2] Wang Tao, Wang Dan, Dong Duo, et al. A brief analysis of the US pharmacovigilance system and its implications for China[J]. Chinese Journal of Pharmaceuticals, 2017, 36 (4): 361-365.

[3] European Medicines Agency. Guidelines on Good Pharmacovigilance Practices[EB/OL]. (2012-06-25)[2020-07-21]. https://eur-lexeuropa.eu/legal-content/EN/TXT/?uri=CELEX%3A32010R1235.

[4] Knight T, Plante K, Ruggieri A. RWD155 use of secondary real-world data from the united states to fulfill European medicines agency post authorization requirement[J]. Value in Health, 2024, 27 (12S): S604.

[5] Zhang Xuanxuan, Shao Rong. Drug quality regulation in Japan and its implications for China[J]. Chinese Journal of Pharmaceutical Industry, 2014, 45 (1): 88-94.

[6] Meng Kangkang, Sun Nan, Dong Duo. Study on the post-marketing monitoring and evaluation system for pharmaceuticals in Japan[J]. Chinese Journal of Pharmacovigilance, 2021, 18 (10): 944-948.

[7] MHLW. Good Vigilance Practice[EB/OL]. (2005-03-23)[2021-05-15]. http://law.e-gov.go.jp/htmldata/H16/H16F19001000135.html.

[8] MHLW. Good Post-Marketing Surveillance Practice[EB/OL]. (2005-03-23)[2021-05-15]. http://law.e-gov.go.jp/htmldata/H16/H16F19001000171.html.

[9] PMDA. Adverse Reaction Report of Patients[EB/OL].(2019-03-26)[2022-06-13]. https://www.pmda.go.jp/safety/reports/patients/0004.html.